Inicio
Resultado de la búsqueda
10 búsqueda de la palabra clave 'prognosis'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma / Carlos Esteban Builes Montaño ; Londoño Bustamante, Andrés Felipe ; Julio Andrés Valencia Ferro ; Duque, Carlos S. ; Tobón Ospina, Catalina ; Alejandro Vélez Hoyos ; Sánchez, Juan G. ; Agudelo, Miguel ; Dueñas, Juan P. ; Palacio, Maria F. ; Sierra, Natalia
Título : Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor Fecha de publicación : 2025 Títulos uniformes : Cureus Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave : classification prognosis risk staging surgery thyroid cancer tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Thyroid Cancer Staging: Historical Evolution and Analysis From Macrocarcinoma to Microcarcinoma [documento electrónico] / Carlos Esteban Builes Montaño, Autor ; Londoño Bustamante, Andrés Felipe, Autor ; Julio Andrés Valencia Ferro, Autor ; Duque, Carlos S., Autor ; Tobón Ospina, Catalina, Autor ; Alejandro Vélez Hoyos, Autor ; Sánchez, Juan G., Autor ; Agudelo, Miguel, Autor ; Dueñas, Juan P., Autor ; Palacio, Maria F., Autor ; Sierra, Natalia, Autor . - 2025.
Obra : Cureus
Idioma : Inglés (eng) Idioma original : Inglés (eng)
Palabras clave : classification prognosis risk staging surgery thyroid cancer tnm Resumen : The classification of thyroid cancer diagnosis and treatment has evolved dramatically since the Union for International Cancer Control (UICC) published the first staging system in 1968. A careful review of the eight published editions of well-differentiated thyroid cancer (WDTC) staging by the UICC and the American Joint Committee on Cancer (AJCC) was performed. Each edition was analyzed to clearly understand which development published and accepted by specialists treating thyroid cancer justified considering a new updated edition. This study presents a comprehensive review of the remarkable evolution of thyroid cancer staging, highlighting the various changes in several areas throughout the years and editions. There were surprising changes within the eight publications: the tumor size was progressively reduced from 4 cm in the first AJCC volume to less than 1 cm in the seventh and eighth UICC and AJCC editions, classifying these small, WDTCs known up to now as “microcarcinomas.” Extrathyroidal extension was accepted after the third edition; this description certainly plays a key role in today’s decisions to manage this tumor as a prognostic factor. The age specification of 45 years prevailed for seven consecutive publications until it was raised to 55 years in the eighth thyroid cancer staging system. Without a doubt, this iconic change allowed physicians around the world to give their 45-year-old thyroid cancer patients a more encouraging panorama of the disease with the new classification. Over the course of nearly 57 years, thyroid cancer staging has undergone remarkable changes, reaching a level of certainty that not only provides recommendations for safer treatments with less surgery and adjunctive measures but also improves survival rates and patient safety. Mención de responsabilidad : Carlos S. Duque , Carlos E. Builes-Montaño , Catalina Tobón-Ospina , Alejandro Velez Hoyos , Juan G. Sánchez , Andres F. Londoño , Miguel Agudelo , Julio A. Valencia , Juan P. Dueñas , Maria F. Palacio , Natalia Sierra Referencia : Cureus 17(4): e81972. DOI (Digital Object Identifier) : 10.7759/cureus.81972 Derechos de uso : CC BY-NC-ND En línea : https://www.cureus.com/articles/350600-thyroid-cancer-staging-historical-evoluti [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002371 AC-2025-054 Archivo digital Producción Científica Artículos científicos Disponible
Título : Predictive models of infection in patients with systemic lupus erythematosus: A systematic literature review Tipo de documento : documento electrónico Autores : Paula Andrea Granda Carvajal, Fecha de publicación : 2021 Títulos uniformes : Lupus Idioma : Inglés (eng) Palabras clave : Systemic lupus erythematosus clinical prediction models infection prognosis systematic literature review Resumen : Introduction: Having reliable predictive models of prognosis/the risk of infection in systemic lupus erythematosus (SLE) patients would allow this problem to be addressed on an individual basis to study and implement possible preventive or therapeutic interventions. Objective: To identify and analyze all predictive models of prognosis/the risk of infection in patients with SLE that exist in medical literature. Methods: A structured search in PubMed, Embase, and LILACS databases was carried out until May 9, 2020. In addition, a search for abstracts in the American Congress of Rheumatology (ACR) and European League Against Rheumatism (EULAR) annual meetings' archives published over the past eight years was also conducted. Studies on developing, validating or updating predictive prognostic models carried out in patients with SLE, in which the outcome to be predicted is some type of infection, that were generated in any clinical context and with any time horizon were included. There were no restrictions on language, date, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guideline recommendations were followed. The PROBAST tool (A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies) was used to assess the risk of bias and the applicability of each model. Results: We identified four models of infection prognosis in patients with SLE. Mostly, there were very few events per candidate predictor. In addition, to construct the models, an initial selection was made based on univariate analyses with no contraction of the estimated coefficients being carried out. This suggests that the proposed models have a high probability of overfitting and being optimistic. Conclusions: To date, very few prognostic models have been published on the infection of SLE patients. These models are very heterogeneous and are rated as having a high risk of bias and methodological weaknesses. Despite the widespread recognition of the frequency and severity of infections in SLE patients, there is no reliable predictive prognostic model that facilitates the study and implementation of personalized preventive or therapeutic measures.Protocol registration number: PROSPERO CRD42020171638. Mención de responsabilidad : Mauricio Restrepo-Escobar, Paula A Granda-Carvajal, Daniel C Aguirre, Johanna Hernández-Zapata, Gloria M Vásquez, Fabián Jaimes Referencia : Lupus. 2021 Mar;30(3):421-430. DOI (Digital Object Identifier) : 10.1177/0961203320983462 PMID : 33407048 En línea : https://journals.sagepub.com/doi/10.1177/0961203320983462 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Predictive models of infection in patients with systemic lupus erythematosus: A systematic literature review [documento electrónico] / Paula Andrea Granda Carvajal, . - 2021.
Obra : Lupus
Idioma : Inglés (eng)
Palabras clave : Systemic lupus erythematosus clinical prediction models infection prognosis systematic literature review Resumen : Introduction: Having reliable predictive models of prognosis/the risk of infection in systemic lupus erythematosus (SLE) patients would allow this problem to be addressed on an individual basis to study and implement possible preventive or therapeutic interventions. Objective: To identify and analyze all predictive models of prognosis/the risk of infection in patients with SLE that exist in medical literature. Methods: A structured search in PubMed, Embase, and LILACS databases was carried out until May 9, 2020. In addition, a search for abstracts in the American Congress of Rheumatology (ACR) and European League Against Rheumatism (EULAR) annual meetings' archives published over the past eight years was also conducted. Studies on developing, validating or updating predictive prognostic models carried out in patients with SLE, in which the outcome to be predicted is some type of infection, that were generated in any clinical context and with any time horizon were included. There were no restrictions on language, date, or status of the publication. To carry out the systematic review, the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) guideline recommendations were followed. The PROBAST tool (A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies) was used to assess the risk of bias and the applicability of each model. Results: We identified four models of infection prognosis in patients with SLE. Mostly, there were very few events per candidate predictor. In addition, to construct the models, an initial selection was made based on univariate analyses with no contraction of the estimated coefficients being carried out. This suggests that the proposed models have a high probability of overfitting and being optimistic. Conclusions: To date, very few prognostic models have been published on the infection of SLE patients. These models are very heterogeneous and are rated as having a high risk of bias and methodological weaknesses. Despite the widespread recognition of the frequency and severity of infections in SLE patients, there is no reliable predictive prognostic model that facilitates the study and implementation of personalized preventive or therapeutic measures.Protocol registration number: PROSPERO CRD42020171638. Mención de responsabilidad : Mauricio Restrepo-Escobar, Paula A Granda-Carvajal, Daniel C Aguirre, Johanna Hernández-Zapata, Gloria M Vásquez, Fabián Jaimes Referencia : Lupus. 2021 Mar;30(3):421-430. DOI (Digital Object Identifier) : 10.1177/0961203320983462 PMID : 33407048 En línea : https://journals.sagepub.com/doi/10.1177/0961203320983462 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001688 AC-2021-014 Archivo digital Producción Científica Artículos científicos Disponible
Título : Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2021 Títulos uniformes : Liver International Idioma : Inglés (eng) Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort [documento electrónico] / Sergio Iván Hoyos Duque, . - 2021.
Obra : Liver International
Idioma : Inglés (eng)
Palabras clave : hepatocellular carcinoma liver transplantation prognosis recurrence treatment Resumen : Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been well defined. This study aims to evaluate prognostic and predictive variables associated with PRS. Methods: This Latin American multicenter retrospective cohort study included HCC patients who underwent LT between the years 2005-2018. We evaluated the effect of baseline characteristics at time of HCC recurrence diagnosis and PRS (Cox regression analysis). Early recurrences were those occurring within 12 months of LT. To evaluate the adjusted treatment effect for HCC recurrence, a propensity score matching analysis was performed to assess the probability of having received any specific treatment for recurrence. Results: From a total of 1085 transplanted HCC patients, the cumulative incidence of recurrence was 16.6% (CI 13.5-20.3), with median time to recurrence of 13.0 months (IQR 6.0-26.0). Factors independently associated with PRS were early recurrence (47.6%), treatment with sorafenib and surgery/trans-arterial chemoembolization (TACE). Patients who underwent any treatment presented "early recurrences" less frequently, and more extrahepatic metastasis. This unbalanced distribution was included in the propensity score matching, with correct calibration and discrimination (receiving operator curve of 0.81 [CI 0.72;0.88]). After matching, the adjusted effect on PRS for any treatment was HR of 0.2 (0.10;0.33); P Mención de responsabilidad : Claudia Maccali, Aline L Chagas, Ilka Boin, Emilio Quiñonez, Sebastián Marciano, Mario Vilatobá, Adriana Varón, Margarita Anders, Sergio Hoyos Duque, Agnaldo S Lima, Josemaría Menendez, Martín Padilla-Machaca, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Alejandro Soza, Martín Fauda, Simone R Perales, Rodrigo Vergara Sandoval, Carla Bermudez, Oscar Beltran, Isabel Arenas Hoyos, Lucas McCormack, Francisco Juan Mattera, Adrián Gadano, Jose H Parente García , Claudia Megumi Tani, Luiz Augusto Carneiro D'Albuquerque, Flair J Carrilho, Marcelo Silva, Federico Piñero Referencia : Liver Int. 2021 Apr;41(4):851-862. DOI (Digital Object Identifier) : 10.1111/liv.14736 PMID : 33217193 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.14736 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001640 AC-2020-134 Archivo digital Producción Científica Artículos científicos Disponible
Título : Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Laura María Díaz Correa, Fecha de publicación : 2020 Títulos uniformes : Clinical Lymphoma, Myeloma & Leukemia Idioma : Inglés (eng) Palabras clave : Acute lymphoblastic leukemia Disease free survival Hematopoietic stem-cell transplantation Measurable residual disease Prognosis Resumen : Introduction: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population. Patients and Methods: We assessed a retrospective cohort to compare DFS and OS in adults with de novo ALL according to MRD status at the end of induction chemotherapy, and the type of postinduction consolidation strategy used. Results: A total of 165 adults with ALL were included in the MRD part of the study, 73 patients in the MRD-negative group and 92 in the MRD-positive group. Median DFS for the MRD-positive group was 11 months (95% confidence interval, 11.7-22.2) and was not reached for the MRD-negative group ( P Mención de responsabilidad : Juan Felipe Combariza, Marcos Arango, Laura Díaz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Rocio Orduz, Fabian Mejía, Liliana Moreno y Carlos Ramirez Referencia : Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. DOI (Digital Object Identifier) : 10.1016/j.clml.2020.11.010 PMID : 33277225 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(20)30634-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia [documento electrónico] / Marcos Arango Barrientos, ; Laura María Díaz Correa, . - 2020.
Obra : Clinical Lymphoma, Myeloma & Leukemia
Idioma : Inglés (eng)
Palabras clave : Acute lymphoblastic leukemia Disease free survival Hematopoietic stem-cell transplantation Measurable residual disease Prognosis Resumen : Introduction: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population. Patients and Methods: We assessed a retrospective cohort to compare DFS and OS in adults with de novo ALL according to MRD status at the end of induction chemotherapy, and the type of postinduction consolidation strategy used. Results: A total of 165 adults with ALL were included in the MRD part of the study, 73 patients in the MRD-negative group and 92 in the MRD-positive group. Median DFS for the MRD-positive group was 11 months (95% confidence interval, 11.7-22.2) and was not reached for the MRD-negative group ( P Mención de responsabilidad : Juan Felipe Combariza, Marcos Arango, Laura Díaz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Rocio Orduz, Fabian Mejía, Liliana Moreno y Carlos Ramirez Referencia : Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. DOI (Digital Object Identifier) : 10.1016/j.clml.2020.11.010 PMID : 33277225 En línea : https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(20)30634-0 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001633 AC-2020-127 Archivo digital Producción Científica Artículos científicos Disponible
Título : Validation of the Status epilepticus severity score (STESS) at high-complexity hospitals in Medellín, Colombia Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Fecha de publicación : 2020 Títulos uniformes : Seizure Idioma : Inglés (eng) Palabras clave : Complication Epilepsy Death Outcome Prognosis Score Resumen : Purpose: The Status Epilepticus Severity Score (STESS) is one of the most well-known clinical scoring systems to predict mortality in status epilepticus (SE). The objective of this study was to validate STESS in a Colombian population. Method: We evaluated historical data of adult patients (age ≥16 years) with a clinical or electroencephalographic diagnosis of SE admitted between 2014 and 2017. Prospectively, we included patients admitted from January to June of 2018. The primary outcome was in-hospital mortality. Receiver operating characteristic (ROC)-analysis, determination of best cutoff values, sensitivity, specificity, and positive and negative likelihood ratios were performed. Results: The sample was 395 patients, with in-hospital mortality of 16.8 %. The area under the ROC curve for STESS was 0.84. A cutoff point of ≥3 produced the highest sensitivity of 84.9 % (95 % CI 73.9 %-92.5 %) and a specificity of 65.7 % (95 % CI 60.2 %–70.8 %), with a positive likelihood ratio of 2.5 and a negative likelihood ratio of 0.2. Conclusions: STESS is a useful tool to predict mortality in patients with SE. In Medellin, Colombia, a STESS Mención de responsabilidad : Juan Pablo Millán Sandoval, Luisa María Escobar del Rio, Edison Augusto Gómez, Lady Diana Ladino, Lina María López Ospina, Diana Marcela Díaz, José Fernando Zapata, Olga Helena Hernández Referencia : Seizure. 2020 Oct;81:287-291. DOI (Digital Object Identifier) : 10.1016/j.seizure.2020.08.020 PMID : 32927243 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1059131120302570 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Validation of the Status epilepticus severity score (STESS) at high-complexity hospitals in Medellín, Colombia [documento electrónico] / Lady Diana Ladino Malagón, . - 2020.
Obra : Seizure
Idioma : Inglés (eng)
Palabras clave : Complication Epilepsy Death Outcome Prognosis Score Resumen : Purpose: The Status Epilepticus Severity Score (STESS) is one of the most well-known clinical scoring systems to predict mortality in status epilepticus (SE). The objective of this study was to validate STESS in a Colombian population. Method: We evaluated historical data of adult patients (age ≥16 years) with a clinical or electroencephalographic diagnosis of SE admitted between 2014 and 2017. Prospectively, we included patients admitted from January to June of 2018. The primary outcome was in-hospital mortality. Receiver operating characteristic (ROC)-analysis, determination of best cutoff values, sensitivity, specificity, and positive and negative likelihood ratios were performed. Results: The sample was 395 patients, with in-hospital mortality of 16.8 %. The area under the ROC curve for STESS was 0.84. A cutoff point of ≥3 produced the highest sensitivity of 84.9 % (95 % CI 73.9 %-92.5 %) and a specificity of 65.7 % (95 % CI 60.2 %–70.8 %), with a positive likelihood ratio of 2.5 and a negative likelihood ratio of 0.2. Conclusions: STESS is a useful tool to predict mortality in patients with SE. In Medellin, Colombia, a STESS Mención de responsabilidad : Juan Pablo Millán Sandoval, Luisa María Escobar del Rio, Edison Augusto Gómez, Lady Diana Ladino, Lina María López Ospina, Diana Marcela Díaz, José Fernando Zapata, Olga Helena Hernández Referencia : Seizure. 2020 Oct;81:287-291. DOI (Digital Object Identifier) : 10.1016/j.seizure.2020.08.020 PMID : 32927243 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1059131120302570 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001404 AC-2020-076 Archivo digital Producción Científica Artículos científicos Disponible 
Permalink
Permalink
Permalink
Permalink
Permalink
